Dr. Herrera is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1500 Duarte Rd
Duarte, CA 91010Phone+1 626-775-3514Fax+1 626-218-5310
Education & Training
- City of Hope National Medical CenterFellowship, Blood & Bone Marrow Transplant, 2014 - 2015
- Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2012 - 2015
- Brigham and Women's HospitalResidency, Internal Medicine, 2009 - 2012
- Harvard Medical SchoolClass of 2009
- Princeton UniversityA.B., History, Summa Cum Laude, 1999 - 2003
Certifications & Licensure
- CA State Medical License 2014 - 2026
- MA State Medical License 2011 - 2016
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Larry and Denise Mason Clinical Investigator Career Development Award Lymphoma Research Foundation
- City of Hope K12 City of Hope Clinical Oncology Career Research Development Program Recipient 2015
- City of Hope SPORE in Lymphoma Cancer Project Career Enhancement Award Recipient 2015
- Join now to see all
Clinical Trials
- A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma Start of enrollment: 2014 Oct 15
- Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL Start of enrollment: 2015 Apr 01
- A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas Start of enrollment: 2015 May 01
- Join now to see all
Publications & Presentations
PubMed
- 5 citationsManagement of classical Hodgkin lymphoma: a look at up to date evidence and current treatment approaches.Walter Hanel, Alex F Herrera, Narendranath Epperla
Experimental Hematology & Oncology. 2022-12-27 - 94 citationsA phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphomaNancy L. Bartlett, Alex F. Herrera, Eva Domingo-Domenech, Amitkumar Mehta, Andres Forero-Torres
Blood. 2020-11-19 - 91 citationsHodgkin lymphoma, version 2.2020Richard T. Hoppe, Ranjana H. Advani, Weiyun Z. Ai, Richard F. Ambinder, Philippe Armand
Journal of the National Comprehensive Cancer Network. 2020-06-01
Journal Articles
- Burkitt leukemia limited to the bone marrow has a better prognosis than Burkitt lymphoma with bone marrow involvement in adultsSong JY, Venkataraman G, Fedoriw Y, Siddiqi T, Alikhan MB, Kim YS, Murata-Collins J, Weisenburger DD, Liu X, Duffield AS, Leuk Lymphoma, 1/1/2015
- Ibrutinib in the Treatment of Mantle Cell LymphomaHerrera AF, Jacobsen EJ, Clin Cancer Res, 1/1/2014
Books/Book Chapters
Abstracts/Posters
- CD19-Targeting CAR-T Cell Therapy in CNS LymphomaAlex F. Herrera, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Outcome of Autologous Stem Cell Transplantation Following PD-(L)1 Based Salvage Therapy for Multiply Relapsed Patients with Classic Hodgkin LymphomaAlex F. Herrera, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Preliminary Results from a Phase I Trial of Pembrolizumab Plus Vorinostat in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, a...Alex F. Herrera, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- Future of Maintenance Therapy After Transplant in Relapsed Hodgkin Lymphoma: How Do We Do It Best?ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019
- Preliminary Results from a Phase 2 Trial of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Hodgkin Lymphoma: Beyond ABVD for Everyone60th American Society of Hematology Annual Meeting - 12/1/2018
- Join now to see all
Press Mentions
- Nivolumab plus AVD Prolongs PFS in Adolescents and Adults with Advanced-Stage Classic Hodgkin’s LymphomaOctober 29th, 2024
- Immunotherapy Breakthrough: 92% Survival for Hodgkin Lymphoma PatientsOctober 18th, 2024
- Immunotherapy Extends Survival in Advanced Hodgkin LymphomaOctober 18th, 2024
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: